DK2532367T3 - Farmaceutisk middel til behandling og/eller forebyggelse af cancer - Google Patents
Farmaceutisk middel til behandling og/eller forebyggelse af cancer Download PDFInfo
- Publication number
- DK2532367T3 DK2532367T3 DK11739883.4T DK11739883T DK2532367T3 DK 2532367 T3 DK2532367 T3 DK 2532367T3 DK 11739883 T DK11739883 T DK 11739883T DK 2532367 T3 DK2532367 T3 DK 2532367T3
- Authority
- DK
- Denmark
- Prior art keywords
- gin
- ser
- glu
- pro
- ala
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (10)
1. Medikament til anvendelse i en fremgangsmåde til behandling og/eller forebyggelse af en cancer, omfattende et antistof med immunologisk reaktivitet med et CAPRIN-1-protein, som har aminosyresekvensen med en hvilken som helst af sekvenserne SEQ ID NOs: 2 til 30 med lige numre, og en eller to eller flere typer af antitumormiddel, hvor antistoffet og antitumormidlet eller antitumormidlerne er kombineret sammen eller separat, og hvor antistoffet binder specifikt til den ekstracellulære region af et CAPRIN-1-protein, der findes på overfladen af en cancercelle og har cellulær cytotoksisk aktivitet.
2. Antistof, som har immunologisk reaktivitet med et CAPRIN-1 protein, som har aminosyresekvensen med en hvilken som helst af sekvenserne SEQ ID NOs: 2 til 30 med lige numre, til anvendelse i en fremgangsmåde til behandling og/eller forbyggelse af en cancer, hvor fremgangsmåden omfatter indgivelse til et individt af antistoffet med immunologisk reaktivitet med et CAPRIN-1-protein og en eller to eller flere typer af antitumormiddel, og hvor antistoffet binder specifikt til den ekstracellulære region af et CAPRIN-1-protein, der findes på overfladen af en cancercelle, og hvor antistoffet har cellulær cytotoksisk aktivitet.
3. Medikament eller antistof til anvendelse ifølge krav 1 eller krav 2, hvor antistoffet binder specifikt til et polypeptid med aminosyresekvensen repræsenteret af SEQ ID NO: 37 i den ekstracellulære region af CAPRIN-1-proteinet, der findes på overfladen af en cancercelle, eller til et polypeptid, der består af en sekvens af 7 eller flere fortløbende aminosyrerester med regionen af amino-syrerest 50-98 eller 233-305 i aminosyresekvenserne repræsenteret ved sekvensen med SEQ ID NOs:2 to 30 med ulige numre, eksklusive SEQ ID NOs: 6 og 18.
4. Medikament eller antistof til anvendelse ifølge et hvilket som helst af kravene 1 til 3, hvor CAPRIN-1 -proteinet er fra et menneske.
5. Medikament eller antistof til anvendelse ifølge et hvilket som helst af kravene 1 til 4, hvor-antitumormidlet er et anti-metabolisk lægemiddel, et antibio tisk anticancermiddel, et plante-alkaloid-baseret anticancermiddel, en topoiso-merase-inhibitor eller et antitumor-alkyleringsmiddel.
6. Medikament eller antistof til anvendelse ifølge et hvilket som helst af kravene 1 til 5, hvor antitumormidlet er udvalgt fra gruppen bestående af cy-clophosphamid, paclitaxel, docetaxel, vinorelbin og farmaceutisk acceptable salte og derivater deraf.
7. Medikament, eller antistof til anvendelse ifølge et af kravene 1 til 6, hvor canceren er brystcancer, en hjernetumor, leukæmi, lymfom, lungecancer, ma-stocytom, nyrecancer, livmoderhalscancer, blærecancer, spiserørscancer, mavecancer eller kolorektal cancer.
8. Medikament eller antistof til anvendelse ifølge et hvilket som helst af kravene 1 til 7, hvor antistoffet er et monoklonalt antistof, et polyklonalt antistof, eller et rekombinant antistof.
9. Medikament eller antistof til anvendelse ifølge et hvilket som helst af kravene 1 til 8, hvor antistoffet er et humant antistof, humaniseret antistof, kimært antistof, enkeltkædet antistof eller bispecifikt antistof.
10. Medikament eller antistof til anvendelse ifølge et hvilket som helst af kravene 1 til 9, hvor fremgangsmåden omfatter indgivelse til et individ af antistoffet og et antitumormiddel, samtidigt eller separat.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010023455 | 2010-02-04 | ||
| PCT/JP2011/052414 WO2011096535A1 (ja) | 2010-02-04 | 2011-02-04 | 癌の治療及び／又は予防のための医薬品 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2532367T3 true DK2532367T3 (da) | 2018-11-19 |
Family
ID=44355529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11739883.4T DK2532367T3 (da) | 2010-02-04 | 2011-02-04 | Farmaceutisk middel til behandling og/eller forebyggelse af cancer |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9180187B2 (da) |
| EP (1) | EP2532367B1 (da) |
| JP (1) | JP5923984B2 (da) |
| KR (1) | KR101843807B1 (da) |
| CN (2) | CN102844048A (da) |
| AU (1) | AU2011211700B2 (da) |
| BR (1) | BR112012018943A8 (da) |
| CA (1) | CA2788720C (da) |
| DK (1) | DK2532367T3 (da) |
| ES (1) | ES2691738T3 (da) |
| HU (1) | HUE040012T2 (da) |
| MX (1) | MX2012008991A (da) |
| PL (1) | PL2532367T3 (da) |
| PT (1) | PT2532367T (da) |
| RU (1) | RU2624029C2 (da) |
| WO (1) | WO2011096535A1 (da) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5644110B2 (ja) * | 2008-08-05 | 2014-12-24 | 東レ株式会社 | 癌の検出方法 |
| RU2498819C2 (ru) | 2008-08-05 | 2013-11-20 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и профилактики злокачественных опухолей |
| WO2011096535A1 (ja) | 2010-02-04 | 2011-08-11 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| CN102821789B (zh) | 2010-02-04 | 2016-03-02 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
| JP5906739B2 (ja) | 2010-02-04 | 2016-04-20 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| PT2532365T (pt) | 2010-02-04 | 2016-07-28 | Toray Industries | Composição farmacêutica para o tratamento e/ou a prevenção do cancro |
| CN102822199B (zh) | 2010-02-04 | 2014-10-15 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
| HUE030102T2 (en) | 2010-02-04 | 2017-04-28 | Toray Industries | A pharmaceutical composition comprising anti-caprin-1 antibodies for the treatment and / or prevention of cancer |
| WO2013018891A1 (ja) | 2011-08-04 | 2013-02-07 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| JP6094220B2 (ja) | 2011-08-04 | 2017-03-15 | 東レ株式会社 | 膵臓癌の検出方法 |
| PL2740795T3 (pl) | 2011-08-04 | 2017-04-28 | Toray Industries, Inc. | Kompozycja lekowa do leczenia nowotworu i/lub zapobiegania nowotworowi |
| HUE030130T2 (en) | 2011-08-04 | 2017-04-28 | Toray Industries | A pharmaceutical composition for the treatment and / or prevention of pancreatic cancer |
| JP6015448B2 (ja) | 2011-08-04 | 2016-10-26 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| CN103717740B (zh) | 2011-08-04 | 2015-10-21 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
| ES2618026T3 (es) | 2011-08-04 | 2017-06-20 | Toray Industries, Inc. | Composición farmacológica para el tratamiento y/o la prevención del cáncer |
| KR102005308B1 (ko) | 2012-02-21 | 2019-07-30 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| AU2013223147B2 (en) | 2012-02-21 | 2017-10-05 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| PL2818483T3 (pl) | 2012-02-21 | 2018-01-31 | Toray Industries | Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi |
| PL2818482T3 (pl) * | 2012-02-21 | 2019-11-29 | Toray Industries | Kompozycja farmaceutyczna do leczenia nowotworu |
| AU2013241036B2 (en) * | 2012-03-30 | 2017-07-20 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of liver cancer |
| PL2832366T3 (pl) * | 2012-03-30 | 2018-04-30 | Toray Industries, Inc. | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania rakowi pęcherzyka żółciowego |
| PT2876446T (pt) | 2012-07-19 | 2019-03-25 | Toray Industries | Método para deteção de cancro |
| BR112015001100A2 (pt) | 2012-07-19 | 2018-03-27 | Toray Industries, Inc. | método de detecção de câncer |
| TR201819812T4 (tr) | 2013-08-09 | 2019-01-21 | Toray Industries | Kanserin Tedavisi Ve/Veya Önlenmesi Amacına Yönelik Farmasötik Bileşim |
| JP7206590B2 (ja) | 2016-10-28 | 2023-01-18 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| US20210121562A1 (en) * | 2018-03-30 | 2021-04-29 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| WO2021182574A1 (ja) | 2020-03-12 | 2021-09-16 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| KR20220153615A (ko) | 2020-03-12 | 2022-11-18 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
| WO2021182571A1 (ja) | 2020-03-12 | 2021-09-16 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| JPWO2021182570A1 (da) | 2020-03-12 | 2021-09-16 | ||
| WO2021182573A1 (ja) | 2020-03-12 | 2021-09-16 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| EP4360649A1 (en) | 2021-06-23 | 2024-05-01 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| MX2023014498A (es) | 2021-06-23 | 2024-01-25 | Toray Industries | Medicamento para el tratamiento y/o prevencion de cancer. |
| EP4378476A1 (en) | 2021-07-27 | 2024-06-05 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| EP4378478A1 (en) | 2021-07-27 | 2024-06-05 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| JPWO2023008461A1 (da) | 2021-07-27 | 2023-02-02 | ||
| KR20240051956A (ko) | 2021-09-03 | 2024-04-22 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| JPWO2024005123A1 (da) | 2022-06-30 | 2024-01-04 | ||
| AU2023329558A1 (en) | 2022-08-24 | 2025-02-27 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| AU2023329564A1 (en) | 2022-08-24 | 2025-02-27 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| AU2023329563A1 (en) | 2022-08-24 | 2025-02-27 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| WO2024048541A1 (ja) | 2022-08-30 | 2024-03-07 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| WO2024048542A1 (ja) | 2022-08-30 | 2024-03-07 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| WO2024135809A1 (ja) * | 2022-12-23 | 2024-06-27 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2336976T3 (es) * | 1994-09-19 | 2010-04-19 | Ricardo J. Moro | Deteccion de cancer. |
| US5698396A (en) | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
| US20030118599A1 (en) | 1999-04-02 | 2003-06-26 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| RU2234942C2 (ru) | 1998-07-14 | 2004-08-27 | Корикса Корпорейшн | Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид |
| EP1870466A3 (en) | 1998-07-14 | 2008-03-19 | Corixa Corporation | Compositions and methods for therapy and diagnosis of prostate cancer |
| US6969518B2 (en) | 1998-12-28 | 2005-11-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| US6335170B1 (en) | 1999-02-22 | 2002-01-01 | Torben F. Orntoft | Gene expression in bladder tumors |
| EP1187915A2 (en) | 1999-04-02 | 2002-03-20 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
| US6444425B1 (en) | 1999-04-02 | 2002-09-03 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| EP1224285A4 (en) | 1999-10-29 | 2004-12-08 | Human Genome Sciences Inc | 27 HUMAN SECRETED PROTEINS |
| US20020006404A1 (en) | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
| PL366626A1 (en) | 2000-03-29 | 2005-02-07 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US7919467B2 (en) * | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US7408041B2 (en) * | 2000-12-08 | 2008-08-05 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| US20040029114A1 (en) | 2001-01-24 | 2004-02-12 | Eos Technology, Inc. | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
| RU2306952C2 (ru) | 2001-01-31 | 2007-09-27 | Байоджен Айдек Инк. | Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами |
| AU2002311787A1 (en) | 2001-03-28 | 2002-10-15 | Zycos Inc. | Translational profiling |
| WO2002083070A2 (en) | 2001-04-10 | 2002-10-24 | Corixa Corporation | Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
| EP1516049A4 (en) | 2001-05-11 | 2006-01-11 | Corixa Corp | COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF LUNG CANCER |
| US20030190640A1 (en) | 2001-05-31 | 2003-10-09 | Mary Faris | Genes expressed in prostate cancer |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| EP1575480A4 (en) | 2002-02-22 | 2008-08-06 | Genentech Inc | COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM |
| US20050003390A1 (en) * | 2002-05-17 | 2005-01-06 | Axenovich Sergey A. | Targets for controlling cellular growth and for diagnostic methods |
| US20040126379A1 (en) * | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
| US20060121029A1 (en) | 2002-08-30 | 2006-06-08 | Hiroshi Shiku | Method and composition for regulating the activity of regulatory t cells |
| EP2179742A1 (en) | 2002-11-26 | 2010-04-28 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| WO2004076682A2 (en) | 2003-02-26 | 2004-09-10 | Surromed, Inc. | Targets for controlling cellular growth and for diagnostic methods |
| WO2004097051A2 (en) | 2003-04-29 | 2004-11-11 | Wyeth | Methods for diagnosing aml and mds differential gene expression |
| EP1639090A4 (en) | 2003-06-09 | 2008-04-16 | Univ Michigan | COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER |
| US20070048738A1 (en) | 2003-07-14 | 2007-03-01 | Mayo Foundation For Medical Education And Research | Methods and compositions for diagnosis, staging and prognosis of prostate cancer |
| US20050032113A1 (en) | 2003-07-17 | 2005-02-10 | Mitsubishi Pharma Corporation | Membrane protein library for proteome analysis and method for preparing same |
| EP2361929A1 (en) | 2004-01-26 | 2011-08-31 | Debiovision Inc. | Neoplasm-specific polypeptides and their use |
| PT1735348E (pt) | 2004-03-19 | 2012-07-24 | Imclone Llc | Anticorpo anti-receptor do factor de crescimento humano |
| WO2005100998A2 (en) * | 2004-04-16 | 2005-10-27 | Europroteome Ag | Membrane markers for use in cancer diagnosis and therapy |
| DE102004026135A1 (de) | 2004-05-25 | 2006-01-05 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
| WO2006002378A2 (en) | 2004-06-23 | 2006-01-05 | Avalon Pharmaceuticals | Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods |
| JP2008528486A (ja) | 2005-01-21 | 2008-07-31 | ジェネンテック・インコーポレーテッド | Ｈｅｒ抗体の一定投薬 |
| WO2006089212A2 (en) | 2005-02-18 | 2006-08-24 | Children's Medical Center Corporation | Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin |
| CA2602088C (en) | 2005-03-11 | 2021-07-27 | Ciphergen Biosystems, Inc. | Biomarkers for ovarian cancer and endometrial cancer |
| JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| US8014957B2 (en) | 2005-12-15 | 2011-09-06 | Fred Hutchinson Cancer Research Center | Genes associated with progression and response in chronic myeloid leukemia and uses thereof |
| WO2007095186A2 (en) * | 2006-02-14 | 2007-08-23 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
| WO2008073162A2 (en) | 2006-08-17 | 2008-06-19 | Cell Signaling Technology, Inc. | Lysine acetylation sites |
| US20080107668A1 (en) | 2006-08-30 | 2008-05-08 | Immunotope, Inc. | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| WO2008031041A2 (en) | 2006-09-07 | 2008-03-13 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Melanoma gene signature |
| WO2008059252A2 (en) | 2006-11-15 | 2008-05-22 | Oxford Biomedica (Uk) Limited | Methods and composition fro t cell receptors which recognize 5t4 antigen |
| JP5663834B2 (ja) | 2008-03-14 | 2015-02-04 | 東ソー株式会社 | 遺伝子組換え抗体の製造方法 |
| US8454968B2 (en) | 2008-08-05 | 2013-06-04 | Toray Industries, Inc. | Method for inducing immunity with a peptide fragment from human CAPRIN-1 |
| JP5644110B2 (ja) | 2008-08-05 | 2014-12-24 | 東レ株式会社 | 癌の検出方法 |
| RU2498819C2 (ru) * | 2008-08-05 | 2013-11-20 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и профилактики злокачественных опухолей |
| CA2771441C (en) | 2009-08-19 | 2016-10-11 | Merck Patent Gmbh | Antibodies for the detection of integrin complexes in ffpe material |
| KR101545914B1 (ko) | 2009-09-22 | 2015-08-20 | 프로바이오겐 아게 | 특수화된 글리칸 구조를 함유하는 분자의 생산 방법 |
| CN102822199B (zh) * | 2010-02-04 | 2014-10-15 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
| HUE030102T2 (en) | 2010-02-04 | 2017-04-28 | Toray Industries | A pharmaceutical composition comprising anti-caprin-1 antibodies for the treatment and / or prevention of cancer |
| PT2532365T (pt) * | 2010-02-04 | 2016-07-28 | Toray Industries | Composição farmacêutica para o tratamento e/ou a prevenção do cancro |
| WO2011096535A1 (ja) | 2010-02-04 | 2011-08-11 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| CN102821789B (zh) | 2010-02-04 | 2016-03-02 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
| JP5906739B2 (ja) * | 2010-02-04 | 2016-04-20 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| HUE030130T2 (en) | 2011-08-04 | 2017-04-28 | Toray Industries | A pharmaceutical composition for the treatment and / or prevention of pancreatic cancer |
| JP6094220B2 (ja) | 2011-08-04 | 2017-03-15 | 東レ株式会社 | 膵臓癌の検出方法 |
| CN103717740B (zh) | 2011-08-04 | 2015-10-21 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
| AU2013241036B2 (en) | 2012-03-30 | 2017-07-20 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of liver cancer |
| PL2832366T3 (pl) | 2012-03-30 | 2018-04-30 | Toray Industries, Inc. | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania rakowi pęcherzyka żółciowego |
-
2011
- 2011-02-04 WO PCT/JP2011/052414 patent/WO2011096535A1/ja active Application Filing
- 2011-02-04 CA CA2788720A patent/CA2788720C/en active Active
- 2011-02-04 PL PL11739883T patent/PL2532367T3/pl unknown
- 2011-02-04 JP JP2011510197A patent/JP5923984B2/ja active Active
- 2011-02-04 ES ES11739883.4T patent/ES2691738T3/es active Active
- 2011-02-04 US US13/576,950 patent/US9180187B2/en active Active
- 2011-02-04 MX MX2012008991A patent/MX2012008991A/es active IP Right Grant
- 2011-02-04 AU AU2011211700A patent/AU2011211700B2/en active Active
- 2011-02-04 EP EP11739883.4A patent/EP2532367B1/en active Active
- 2011-02-04 HU HUE11739883A patent/HUE040012T2/hu unknown
- 2011-02-04 RU RU2012137503A patent/RU2624029C2/ru active
- 2011-02-04 CN CN2011800172337A patent/CN102844048A/zh active Pending
- 2011-02-04 BR BR112012018943A patent/BR112012018943A8/pt not_active Application Discontinuation
- 2011-02-04 DK DK11739883.4T patent/DK2532367T3/da active
- 2011-02-04 KR KR1020127022763A patent/KR101843807B1/ko active Active
- 2011-02-04 CN CN201910271408.5A patent/CN109925511B/zh active Active
- 2011-02-04 PT PT11739883T patent/PT2532367T/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112012018943A8 (pt) | 2017-12-19 |
| PL2532367T3 (pl) | 2019-02-28 |
| KR20120139720A (ko) | 2012-12-27 |
| KR101843807B1 (ko) | 2018-03-30 |
| US9180187B2 (en) | 2015-11-10 |
| US20120294860A1 (en) | 2012-11-22 |
| JPWO2011096535A1 (ja) | 2013-06-13 |
| RU2012137503A (ru) | 2014-03-10 |
| JP5923984B2 (ja) | 2016-05-25 |
| AU2011211700B2 (en) | 2015-06-11 |
| CA2788720A1 (en) | 2011-08-11 |
| CN109925511A (zh) | 2019-06-25 |
| HUE040012T2 (hu) | 2019-02-28 |
| CA2788720C (en) | 2019-08-20 |
| CN102844048A (zh) | 2012-12-26 |
| RU2624029C2 (ru) | 2017-06-30 |
| ES2691738T3 (es) | 2018-11-28 |
| MX2012008991A (es) | 2012-09-07 |
| CN109925511B (zh) | 2024-03-19 |
| EP2532367A4 (en) | 2014-05-28 |
| EP2532367B1 (en) | 2018-08-29 |
| EP2532367A1 (en) | 2012-12-12 |
| WO2011096535A1 (ja) | 2011-08-11 |
| AU2011211700A1 (en) | 2012-08-23 |
| PT2532367T (pt) | 2018-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2532367T3 (da) | Farmaceutisk middel til behandling og/eller forebyggelse af cancer | |
| CA2788716C (en) | Pharmaceutical composition for treating and/or preventing cancer | |
| CA2788718C (en) | Caprin-1 antibody for treating and/or preventing cancer | |
| CA2788547C (en) | Pharmaceutical composition for treating and/or preventing cancer | |
| CA2733223C (en) | Pharmaceutical composition comprising anti-caprin-1 antibody for treatment and prevention of cancers | |
| DK2532365T3 (da) | Farmaceutisk sammensætning til behandling og/eller forebyggelse af kræft | |
| DK2532364T3 (da) | Farmaceutisk sammensætning omfattende anti caprin-1-antistoffer til behandling og/eller forebyggelse af kræft | |
| DK2740489T3 (da) | Farmaceutisk sammensætning til behandling og/eller forebyggelse af pancreascancer | |
| CA2869123A1 (en) | Pharmaceutical composition comprising anti-caprin-1 antibodies for the treatment of gallbladder cancer |